Cargando…
BCL2A1 and CCL18 Are Predictive Biomarkers of Cisplatin Chemotherapy and Immunotherapy in Colon Cancer Patients
Background: Cisplatin enhances the antitumor T cell response, and the combination of PD-L1 blockade produces a synergistic therapeutic effect. However, the clinical correlation between cisplatin and immunotherapy in colon cancer (CC) is unknown. Methods: Using the “pRRophetic” package, we calculated...
Autores principales: | Yue, Taohua, Liu, Xiangzheng, Zuo, Shuai, Zhu, Jing, Li, Jichang, Liu, Yucun, Chen, Shanwen, Wang, Pengyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898943/ https://www.ncbi.nlm.nih.gov/pubmed/35265629 http://dx.doi.org/10.3389/fcell.2021.799278 |
Ejemplares similares
-
Two Similar Signatures for Predicting the Prognosis and Immunotherapy Efficacy of Stomach Adenocarcinoma Patients
por: Yue, Taohua, et al.
Publicado: (2021) -
The aging-related risk signature in colorectal cancer
por: Yue, Taohua, et al.
Publicado: (2021) -
Endogenous hydrogen sulfide regulates xCT stability through persulfidation of OTUB1 at cysteine 91 in colon cancer cells
por: Chen, Shanwen, et al.
Publicado: (2021) -
Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients
por: Yue, Taohua, et al.
Publicado: (2023) -
Overexpression of CBS/H(2)S inhibits proliferation and metastasis of colon cancer cells through downregulation of CD44
por: Zhang, Yuyang, et al.
Publicado: (2022)